Who Optimizes SG&A Costs Better? Cytokinetics, Incorporated or TG Therapeutics, Inc.

Biotech SG&A Cost Strategies: Cytokinetics vs. TG Therapeutics

__timestampCytokinetics, IncorporatedTG Therapeutics, Inc.
Wednesday, January 1, 20141726800024518692
Thursday, January 1, 20151966700019886580
Friday, January 1, 20162782300012631689
Sunday, January 1, 20173646800021977998
Monday, January 1, 20183128200020759000
Tuesday, January 1, 20193961000020838000
Wednesday, January 1, 202052820000121812000
Friday, January 1, 202196803000152137000
Saturday, January 1, 202217797700083231000
Sunday, January 1, 2023173612000122706000
Loading chart...

Infusing magic into the data realm

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Cytokinetics, Incorporated and TG Therapeutics, Inc. have shown distinct strategies in optimizing these costs. From 2014 to 2023, Cytokinetics saw a significant increase in SG&A expenses, peaking in 2022 with a 930% rise from 2014. Meanwhile, TG Therapeutics experienced a more volatile pattern, with a notable spike in 2021, marking a 520% increase from 2014, before a decline in 2022.

A Decade of Financial Strategy

Cytokinetics' steady increase suggests a strategic investment in growth and operations, while TG Therapeutics' fluctuations may reflect adaptive strategies in response to market conditions. Understanding these trends provides valuable insights into how biotech companies balance operational costs with growth ambitions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025